Taken together, these data indicate that PVT1 was up-regulated under gemcitabine treatment conditions and that a high level of PVT1 promoted pancreatic cancer cell resistance to gemcitabine in vitro and in vivo. This evidence concerns the gene PVT1 and pancreatic neoplasm.